Golden-Gate assembly system, recombinant strain containing Golden-Gate assembly system, construction method and application of recombinant strain, and method for producing stevioside
By utilizing the specific ligation sequence and dual-screening system of the Golden-Gate assembly system, the synchronous and directional assembly of the steviol glycoside synthesis pathway was achieved, solving the problem of low efficiency in multi-fragment DNA assembly and improving the yield and conversion rate of steviol glycosides.
Patent Information
- Application Number
- CN202511040560.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-28
- Publication Date
- 2025-11-21
AI Technical Summary
The existing Golden-Gate assembly technology has low efficiency in assembling multiple DNA fragments and high vector self-ligation rate, making it difficult to achieve efficient synchronous and directional assembly of the steviol glycoside synthesis pathway, resulting in low steviol glycoside yield.
The Golden-Gate assembly system was used to achieve synchronous and directional assembly of the steviol glycoside synthesis pathway through eight specific linker sequences. Combined with screening marker genes and a dual screening system, specific linker sequences I-VIII and promoter combinations were used to regulate metabolic flux, optimize gene expression, and avoid the accumulation of intermediate products.
It significantly improved the assembly efficiency and positive clone accuracy of the steviol glycoside synthesis pathway, increased the yield and conversion rate of steviol glycosides, and achieved efficient steviol glycoside production.
Smart Images

Figure CN120989122A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the field of genetic engineering, in particular to a Golden-Gate assembly system, a recombinant strain containing the Golden-Gate assembly system, a construction method and application thereof, and a method for producing steviol glycoside. BACKGROUND
[0002] With the reduction of Sanger DNA sequencing cost, synthetic biology has taken advantage of the situation, which can overcome the obstacles of complex steps of chemical synthesis and low content and difficult purification of plant extraction, and become a potential technology for efficient production of target compounds. Around synthetic biology, many DNA assembly tools have been developed, including Gibson assembly method, BioBricks biological brick technology, Gateway seamless cloning, in vivo one-step assembly method, etc. The above methods have been developed more maturely, but when connecting multiple fragments, they can only be carried out step by step, which is high in cost and time-consuming. The principle of Golden-Gate is relatively simple, which connects fragments through 4bp base pair complementation without limiting the number of fragments, and has more obvious advantages when connecting multiple fragments. At present, there are many reports on the establishment and optimization of more efficient DNA assembly methods based on Golden-Gate. However, Golden-Gate technology still has some limitations, such as the problem of vector self-connection, so it is urgent to develop a Golden-Gate assembly system to realize the synchronous directional assembly of steviol glycoside synthesis pathway, improve the conversion rate of synthesis pathway and the yield of steviol glycoside. SUMMARY
[0003] The purpose of the present application is to overcome the problems of low efficiency of multi-fragment DNA assembly and high rate of vector self-connection in the prior art, and to provide a Golden-Gate assembly system, a recombinant strain containing the Golden-Gate assembly system, a construction method and application thereof, and a method for producing steviol glycoside. The Golden-Gate assembly system realizes the synchronous directional assembly of steviol glycoside synthesis pathway through 8 specific connection sequences, greatly improves the assembly efficiency of steviol glycoside synthesis pathway, and has the advantages of greatly improving the accuracy of positive clones in the double screening system, improving the conversion rate of synthesis pathway, and further improving the yield of steviol glycoside.
[0004] In order to achieve the above purpose, the first aspect of the present application provides a Golden-Gate assembly system, which contains connection sequence I, screening marker gene, connection sequence II, promoter I, connection sequence III, kaurene oxidase gene, connection sequence IV, terminator I, connection sequence V, promoter II, connection sequence VI, kaurenoic acid 13-hydroxylase gene, connection sequence VII, terminator II, and connection sequence VIII connected in sequence.
[0005] Preferably, the nucleotide sequence of the connecting sequence I is as shown in SEQ ID NO. 1, the nucleotide sequence of the connecting sequence II is as shown in SEQ ID NO. 2, the nucleotide sequence of the connecting sequence III is as shown in SEQ ID NO. 3, the nucleotide sequence of the connecting sequence IV is as shown in SEQ ID NO. 4, the nucleotide sequence of the connecting sequence V is as shown in SEQ ID NO. 5, the nucleotide sequence of the connecting sequence VI is as shown in SEQ ID NO. 6, the nucleotide sequence of the connecting sequence VII is as shown in SEQ ID NO. 7, and the nucleotide sequence of the connecting sequence VIII is as shown in SEQ ID NO. 8.
[0006] Preferably, the promoter I and the promoter II are each independently selected from any one of PGPD, PTRPC, PGD A, PGLNA, PCOX7C and PDES.
[0007] Preferably, the promoter I is PGPD, and the nucleotide sequence of the PGPD is as shown in SEQ ID NO. 9.
[0008] Preferably, the promoter II is PTRPC, and the nucleotide sequence of the PTRPC is as shown in SEQ ID NO. 10.
[0009] Preferably, the selection marker gene is selected from any one of a hygromycin resistance gene HPH, an ampicillin resistance gene AmpR, a kanamycin resistance gene KanR and a bleomycin resistance gene BleR.
[0010] Preferably, the terminator I and the terminator II are each independently selected from any one of TTRPT, TTRPC, TTDES, TPYK1, GGPPt and TTEF.
[0011] Preferably, the nucleotide sequence of the kaurene oxidase gene is as shown in SEQ ID NO. 11.
[0012] Preferably, the nucleotide sequence of the kaurenoic acid 13-hydroxylation enzyme is as shown in SEQ ID NO. 12.
[0013] The second aspect of the present application provides a recombinant strain containing the Golden-Gate assembly system as described above.
[0014] The third aspect of the present application provides a method for constructing a recombinant strain, which comprises introducing the Golden-Gate assembly system as described above into a starting strain.
[0015] Preferably, the starting strain is Gibberella jifike.
[0016] The fourth aspect of the present application provides use of the Golden-Gate assembly system as described above, the recombinant strain as described above and the recombinant strain constructed by the method as described above in production of steviol glycosides.
[0017] The fifth aspect of the present application provides a method for producing steviol glycosides, which inoculates the recombinant strain as described above and / or the recombinant strain constructed by the method as described above into a fermentation medium for fermentation culture.
[0018] Preferably, the fermentation medium contains 4.5-5.5 wt% starch, 1-2 wt% peanut powder, 0.8-1.2 wt% soybean powder, 0.1-0.14 wt% soybean oil, 0.1-0.2 wt% magnesium sulfate heptahydrate, 0.02-0.03 wt% ammonium sulfate, 0.15-0.25 wt% potassium bisulfate, 0.004-0.006 wt% zinc sulfate and 0.007-0.008 wt% magnesium sulfate.
[0019] Preferably, the fermentation culture conditions include a temperature of 25-35℃, a rotation speed of 150-250 rpm and a time of 4-6 days.
[0020] Through the above technical solutions, the Golden-Gate assembly system provided by the present application realizes synchronous directional assembly of the steviol glycoside synthesis pathway through 8 specific connection sequences, greatly improves the assembly efficiency of the steviol glycoside synthesis pathway, has the advantage that the double screening system greatly improves the accuracy of positive clones, can further regulate and optimize the metabolic flow by combining strong and weak promoters, improves the conversion rate of the synthesis pathway, and thus improves the yield of steviol glycosides. BRIEF DESCRIPTION OF DRAWINGS
[0021] Figure 1 is a diagram of all backbone plasmids and fragment plasmids in Example 1; Figure 2 is a diagram of activities of six promoters controlling GUS gene expression in Example 2; Figure 3 is a diagram of plasmids introduced into Gibberella jifike for production of steviol glycosides in Example 2; Figure 4 is a diagram of content of steviol glycosides after heterologous introduction of steviol glycoside production pathway in Example 3. DETAILED DESCRIPTION
[0022] The endpoints of the ranges and any values disclosed herein are not limited to the precise values recited as the exact dimensions are not critical to the invention. Any numeric range recited is intended to include all values from the lower value to the upper value, inclusive of both values, and to sub-ranges falling within the specified range. In this context, individual points within a range, individual points and sub-ranges are combinable with each other to form new ranges, which are to be considered disclosed in this document.
[0023] The first aspect of the present application provides a Golden-Gate assembly system, which comprises sequentially connected connecting sequence I, screening marker gene, connecting sequence II, promoter I, connecting sequence III, kaurene oxidase gene, connecting sequence IV, terminator I, connecting sequence V, promoter II, connecting sequence VI, kaurenoic acid 13-hydroxylase gene, connecting sequence VII, terminator II, connecting sequence VIII. The Golden-Gate assembly system provided by the present application realizes the synchronous directional assembly of seven functional modules (screening marker gene module, promoter I module, kaurene oxidase gene (KO gene) module, terminator I module, promoter II module, kaurenoic acid 13-hydroxylase gene (KAH gene) module and terminator II module) through gradient numbering connecting sequences (connecting sequences I-VII), and the combination of screening marker gene and double screening system (lacz blue-white spot screening + hygromycin resistance gene) significantly improves the positive clone accuracy, and meanwhile, the combination regulation strategy of promoter I and promoter II can be further utilized to optimize the metabolic flow, avoid the accumulation of kaurenoic acid and other intermediate products, greatly improve the conversion rate of key metabolites, and finally realize the efficient production of steviol glycoside in G. bilimbata, thereby systematically solving the problems of low multi-fragment assembly efficiency, screening difficulty and metabolic pathway imbalance.
[0024] According to the present application, preferably, the nucleotide sequence of the connecting sequence I is shown as SEQ ID NO. 1, the nucleotide sequence of the connecting sequence II is shown as SEQ ID NO. 2, the nucleotide sequence of the connecting sequence III is shown as SEQ ID NO. 3, the nucleotide sequence of the connecting sequence IV is shown as SEQ ID NO. 4, the nucleotide sequence of the connecting sequence V is shown as SEQ ID NO. 5, the nucleotide sequence of the connecting sequence VI is shown as SEQ ID NO. 6, the nucleotide sequence of the connecting sequence VII is shown as SEQ ID NO. 7, and the nucleotide sequence of the connecting sequence VIII is shown as SEQ ID NO. 8.
[0025] According to the present application, preferably, the promoter I and the promoter II are each independently selected from any one of PGPD, PTRPC, PGPDA, PGLNA, PCOX7C and PDES. Further preferably, the promoter I is PGPD, and the nucleotide sequence of the PGPD is shown in SEQ ID NO. 9, and the promoter II is PTRPC, and the nucleotide sequence of the PTRPC is shown in SEQ ID NO. 10. Exemplarily, the present application forms a "strong-medium" expression gradient by the combination of the preferred high-intensity promoter I-PGPD and the medium-intensity promoter II-PTRPC, precisely regulates the metabolic flow, and the PGPD drives the efficient expression of kaurene oxidase (KO gene) while the PTRPC moderately regulates kaurenoic acid 13-hydroxylase (KAH gene), effectively avoids the accumulation of KO catalytic products, and the inventors have found that the preferred mode further improves the conversion rate of kaurenoic acid and makes the metabolic pathway run more smoothly.
[0026] According to the present application, preferably, the screening marker gene is selected from any one of hygromycin resistance gene HPH, ampicillin resistance gene AmpR, kanamycin resistance gene KanR and bleomycin resistance gene BleR. The inventors have found that the preferred embodiment forms a double screening system in cooperation with the lacz blue-white spot screening, further improves the accuracy of positive clones, and the present application can flexibly select the marker gene according to the characteristics of the starting strain (such as HPH for Aspergillus awamori and AmpR for Escherichia coli), and accurately screens in the stages of protoplast transformation and cloning, wherein the HPH gene is stably expressed in Aspergillus awamori, and the screened positive clones can be directly used for fermentation, which can further ensure the genetic stability of the industrial production of steviol glycosides.
[0027] According to the present application, preferably, the terminator I and the terminator II are each independently selected from any one of TTRPT, TTRPC, TTDES, TPYK1, GGPPt and TTEF. Preferably, the nucleotide sequence of the kaurene oxidase gene is shown as SEQ ID NO. 11, and the nucleotide sequence of the kaurenoic acid 13-hydroxylase gene is shown as SEQ ID NO. 12. The inventors have found that the preferred terminator I and II of the present application can accurately recognize the transcription termination signal, block the extension of RNA polymerase through the stem-loop structure, reduce the ribosome waste caused by mRNA read-through, and synergistically improve the gene expression efficiency in combination with the preferred promoter I and promoter II as described above, and reduce the metabolic burden of the host. The preferred kaurene oxidase gene (nucleotide sequence shown as SEQ ID NO. 11) and kaurenoic acid 13-hydroxylase gene (nucleotide sequence shown as SEQ ID NO. 12) of the present application are optimized by fungal-biased codons, and the enzyme activity is significantly improved when expressed heterologously in Gibberella fujikuroi. After assembling with the promoter-terminator module, the conversion rate of the key intermediate of the steviol glycoside synthesis pathway is further improved, and finally the yield of steviol glycoside is further improved.
[0028] The nucleotide sequence provided by the present application can be obtained by polymerase chain reaction (PCR) amplification method, recombination method, or artificial synthesis method. Once the nucleotide sequence is obtained, the amino acid sequence can be obtained in large quantities by recombination method. The obtained nucleotide sequence is usually cloned into a vector and then transferred into a genetically engineered bacterium, and then the nucleotide sequence is obtained by separating the host cells after proliferation by conventional methods.
[0029] In addition, the nucleotide sequence can also be synthesized by a known artificial chemical synthesis method.
[0030] The second aspect of the present application provides a recombinant strain, wherein the recombinant strain contains the Golden-Gate assembly system as described above.
[0031] The third aspect of the present application provides a method for constructing a recombinant strain, which comprises: introducing the Golden-Gate assembly system as described above into a starting strain.
[0032] The starting strain can be a prokaryotic cell or a eukaryotic cell. According to the present application, preferably, the starting strain is G. fimbriatum. The inventors have found that G. fimbriatum, as a eukaryotic fungus, has high metabolic compatibility with the steviol glycoside synthesis pathway, and can significantly improve the yield of steviol glycoside.
[0033] The fourth aspect of the present application provides the use of the Golden-Gate assembly system as described above, the recombinant strain as described above and the recombinant strain constructed by the method as described above in the production of steviol glycoside.
[0034] The fifth aspect of the present application provides a method for producing steviol glycoside, which comprises inoculating the recombinant strain as described above and / or the recombinant strain constructed by the method as described above into a fermentation medium for fermentation culture. The inventors have found that the method for producing steviol glycoside according to the present application can realize high yield of steviol glycoside by inoculating the recombinant strain as described above into a fermentation medium, and by using the Golden-Gate assembly system to construct a "strong-medium" promoter gradient combined with an optimal terminator for flexible regulation of metabolic flow, in combination with the natural terpene synthesis background of G. fimbriatum, and the genetic stability of the strain is strong, thereby providing an efficient and stable technical solution for industrial production.
[0035] According to the present application, preferably, the fermentation medium comprises 4.5-5.5 wt% of starch, 1-2 wt% of peanut powder, 0.8-1.2 wt% of soybean powder, 0.1-0.14 wt% of soybean oil, 0.1-0.2 wt% of magnesium sulfate heptahydrate, 0.02-0.03 wt% of ammonium sulfate, 0.15-0.25 wt% of potassium bisulfate, 0.004-0.006 wt% of zinc sulfate and 0.007-0.008 wt% of magnesium sulfate.
[0036] According to the present application, preferably, the fermentation culture conditions include: temperature 25-35℃, rotation speed 150-250rpm, time 4-6 days.
[0037] In the present application, the fermentation conditions of the recombinant strain are not particularly limited, as long as the recombinant strain can proliferate in large quantities through the fermentation process. For example, the fermentation process includes: first inoculating the recombinant strain into a seed culture medium (the seed culture medium preferably contains 2-4% by weight of dextrin, 0.8-1.5% by weight of peanut powder, 1-3% by weight of soybean powder, 2-5% by weight of glucose, 0.8-0.16% by weight of potassium bisulfate and 0.05-0.15% by weight of magnesium sulfate) for culture, and then adding a fermentation culture medium (the fermentation culture medium preferably contains 4.5-5.5% by weight of starch, 1-2% by weight of peanut powder, 0.8-1.2% by weight of soybean powder, 0.1-0.14% by weight of soybean oil, 0.1-0.2% by weight of magnesium sulfate heptahydrate, 0.02-0.03% by weight of ammonium sulfate, 0.15-0.25% by weight of potassium bisulfate, 0.004-0.006% by weight of zinc sulfate and 0.007-0.008% by weight of magnesium sulfate) for induction under the conditions of temperature 20-35℃ and rotation speed 150-250rpm for 15-20h, and then performing shake fermentation in the fermentation culture medium at room temperature under the rotation speed of 150-250rpm for 4-6 days, filtering the culture and collecting the fermentation supernatant.
[0038] The inventors found that the synergistic effect of the above preferred embodiments can maintain the logarithmic growth phase of G. fujikuroi by releasing carbon sources from starch, provide sufficient nitrogen sources for the recombinant strain by peanut powder and soybean powder to promote the expression of exogenous genes, further improve the yield of steviol glycosides, and reduce the industrial production cost by short-period fermentation, thereby further improving the industrial potential.
[0039] The present application will be described in detail by the following examples. In the following examples, the G. fujikuroi is from the laboratory of Professor Huang He of Nanjing Normal University, disclosed in patent CN118813664A, and the accession number is CCTCC NO. M 20221848; MYG solid regenerative plate is purchased from Macrolin; PEG6000 is purchased from Macrolin; STC solution is purchased from Macrolin; other reagents and raw materials are all conventional commercial products.
[0040] Example 1 Construction of Golden-Gate assembly system The construction steps are as follows: S1, acquisition of functional modules, search for key genes for steviol glycoside synthesis in the NCBI database, obtain kaurene oxidase gene (KO gene, nucleotide sequence as shown in SEQ ID NO. 11) and kaurenoic acid 13-hydroxylase gene (KAH gene, nucleotide sequence as shown in SEQ ID NO. 12). At the same time, obtain promoters from Aspergillus nidulans and Aspergillus niger (PGPD, PTRPC, PGPDA, PGLNA, PCOX7C and PDES, nucleotide sequences correspond to SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15 and SEQ ID NO. 16, respectively) and terminators (TTRPT, TTRPC, TTDES, TPYK1, GGPPt and TTE, nucleotide sequences correspond to SEQ ID NO. 17-22, respectively), the above promoters and terminators are all entrusted to Unique Wisdom Company, which provides core functional modules for system construction, i.e. promoter I module, kaurene oxidase gene (KO gene) module, terminator I module, promoter II module, kaurenoic acid 13-hydroxylase gene (KAH gene) module and terminator II module.
[0041] S2, construction of fragment vectors, design 8 specific linkers (i.e. I-VIII connection sequences, respectively CTAG, GAGT, GCAG, CCAC, GCCT, ACGG, AATG and ACAA), take pUC19 (query website: Addgene; number: #50004) as the backbone vector, after BSmb1 double enzyme digestion, the core functional modules of promoter I, KO gene, terminator I, promoter II, KAH gene and terminator II obtained in step S1 are respectively amplified by PCR with primers containing corresponding linkers, and are directionally inserted into the enzyme digestion site, successfully constructing fragment vectors containing different functional elements, as shown in Figure 1 , obtaining recombinant fragments such as pUC-23-PGPD (wherein 2 is link sequence II, 3 is link sequence III), pUC-45-TTRPC, pUC-34-KO, which lay the foundation for multi-fragment recombinant vector assembly.
[0042] S3, backbone vector construction: using PFC332 (query website: Addgene; number: #87845) as the starting backbone, after enzyme digestion with Age1, insert sgRNA to obtain plasmid PFC332-sgRNA, then sequentially insert lacz gene (nucleotide sequence as shown in SEQ ID NO. 23) by enzyme digestion with Bsmb1 to obtain recombinant vector I (pFC332-211Lac), insert TrpcHPH gene (nucleotide sequence as shown in SEQ ID NO. 24) by enzyme digestion with Not 1 to obtain recombinant vector II (pFC332-211Lacz-HPH), insert FSR-N20 gene (nucleotide sequence as shown in SEQ ID NO. 25) by enzyme digestion with Age1 to obtain recombinant vector III (pFC332-211Lacz-HPH-sgFSR), then cut the homologous arms UP (nucleotide sequence as shown in SEQ ID NO. 26) and DN (nucleotide sequence as shown in SEQ ID NO. 27) of 1000-2000bp on the upstream and downstream of FUM gene on the backbone vector PFC332-sgRNA to obtain backbone vector IV pFC332-211Lacz-HPH-sgFUM1, and then insert the homologous arms by enzyme digestion with swa1 on the backbone vector pFC332-211Lacz-HPH-sgFUM1, and then insert the homologous arms by enzyme digestion with Pme1, finally obtain the backbone vector pFC332-211Lacz-HPH-△FUM1.
[0043] S4, connection of fragment vector and backbone vector: 4 μg of the fragment vector prepared in step S2 and the backbone vector prepared in step S3 are first digested with 2 μL of BSMB1 for 6 hours, and when constructing the experimental system, the following steps are sequentially added: first, according to the specific length and concentration of the fragment (backbone), the required amount is calculated, the specific calculation formula is 0.04 multiplied by the length of the fragment (backbone), and then divided by the concentration of the fragment (backbone), and the result obtained is the amount required to be added; then, 1 μL of BSMB1 enzyme is added to the system to ensure that the subsequent enzyme digestion reaction can proceed smoothly; then, 4 μL of T4 buffer is added to provide a suitable reaction buffer environment; then, 4 μL of T4 ligase (provided by takara company) is added to promote the effective connection of DNA fragments; finally, use ddH2O (i.e. double distilled water) to make up the system to a total volume of 20 μL to ensure that each component is at an appropriate concentration for reaction. Through this series of precise operations, the stability of the experimental system and the efficiency of the reaction can be ensured.
[0044] S4, a blue-white spot screening system is established for accurate screening of positive clones. The lacz gene fragment is directionally inserted between the two BsmBI enzyme cutting sites of the skeleton vector pFC332-211Lacz-HPH-△FUM1 obtained in step S3, to construct a blue-white spot screening system based on the principle of alpha-complementation. The lacz gene encodes the alpha peptide segment of beta-galactosidase, which can complement the beta-galactosidase omega segment expressed by the host E. coli to form an active whole enzyme, catalyzing the hydrolysis of X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) in the culture medium to form a deep blue substance, so that colonies containing the complete lacz gene appear blue. When constructing the skeleton vector pFC332-211Lacz-HPH-△FUM1, BsmBⅠ enzyme cutting sites are pre-set on both sides of the lacz gene. After BsmBⅠ enzyme cutting, the vector forms a mixed product of cut and uncut. After the mixture is transformed into an E. coli strain containing the beta-galactosidase omega segment, the uncut vector retains the complete lacz gene and can complement the host to form active beta-galactosidase, which hydrolyzes X-Gal to produce blue spots; while the recombinant plasmid inserted with the exogenous fragment (the Golden-Gate assembly system functional module obtained in step S1) is cut, the lacz gene is destroyed and cannot be complemented, so the colonies appear white.
[0045] Through blue-white spot screening, the un-recombined vector (blue spot) and the recombinant plasmid successfully inserted with the target fragment (white spot) can be quickly distinguished. This embodiment realizes the synchronous directional assembly of 7 functional modules through 8 gradient-specific linkers (connection sequences I-VIII, nucleotide sequences corresponding to SEQ ID NO. 1-8), and successfully constructs the Golden-Gate assembly system by combining the hygromycin resistance and blue-white spot double screening system, which embodies the technical advantages of high efficiency assembly and high accuracy of positive clones, and provides a reliable foundation for the efficient construction of steviol glycoside synthesis pathway.
[0046] Example 2 Application of Golden-Gate assembly system to improve the production of steviol glycerol comprising the following steps: S1, screening promoters: six endogenous promoters (PDES, PCOX7C, PGPD, PTRPC, PGLNA and PGPDA) were used to control the transcription intensity of the gene GUS β-glucuronidase gene (NCBI number GeneBank: MW690024.1), the application purpose of the GUS gene in this embodiment is to act as a reporter gene, and the transcription intensity of different promoters is screened and evaluated by detecting the expression activity thereof, and by the intensity of GUS gene expression, they are divided into high, medium and low type promoters. First, use the vector FfuCas9 (query website: Addgene; number: #121092) as a backbone, insert sgRNA after cutting with stu1 enzyme to obtain plasmid FfuCas9, then insert BIK1-N20 (nucleotide sequence as shown in SEQ ID NO. 28) after cutting with Spe1 enzyme to obtain recombinant vector 1 pFfCas9-sgBIK1, and then cut the upper and lower homologous arms of the base BIK1 to obtain the upper and lower homologous arms, and then cut the lower homologous arm with Not1 enzyme to obtain the recombinant vector 2 pFfCas9-△BIK1.
[0047] The recombinant vector 2 pFfCas9-△BIK1 is cut with Pme1 enzyme and inserted into the gene GUS to obtain the recombinant vector 3 pFfCas9-△BIK1-GUS. The recombinant vector 3 pFfCas9-△BIK1-GUS is cut with Pme1 enzyme and inserted into the promoter PGPDA to obtain the recombinant vector 4 pFfCas9-△BIK1-GPDA-GUS.
[0048] According to the above-mentioned construction method of the vector, the other five recombinant vectors 5 pFfCas9-△BIK1-GLNA-GUS, recombinant vector 6 pFfCas9-△BIK1-GPD-GUS, recombinant vector 7 pFfCas9-△BIK1-TRPC-GUS, recombinant vector 8 pFfCas9-BIK1-DES-GUS and recombinant vector 9 pFfCas9-△BIK1-COX7C-GUS are obtained.
[0049] The six plasmids of the recombinant vector 4 pFfCas9-△BIK1-GPDA-GUS, the recombinant vector 5 pFfCas9-△BIK1-GLNA-GUS, the recombinant vector 6 pFfCas9-△BIK1-GPD-GUS, the recombinant vector 7 pFfCas9-△BIK1-TRPC-GUS, the recombinant vector 8 pFfCas9-△BIK1-DES-GUS and the recombinant vector 9 pFfCas9-△BIK1-COX7C-GUS are introduced into the starting strain Gibberella fujikuroi, and the GUS protein expression activity is detected (the results are as shown inFigure 2 As shown in Table 1, the corresponding six promoters can be divided into three types of high, medium and low intensity according to the ability to drive gene transcription, i.e. high intensity: PDES and PCOX7C, medium intensity: PGPD and PTRPC, and low intensity: PGLNA and PGPDA. Using three different endogenous promoters with high, medium and low transcription activity to control the transcription intensity of two genes encoding steviol glycoside pathway, fine-tune gene expression and improve pathway efficiency.
[0050] S2, construct plasmid, cut plasmid pFC332-sgRNA with Not1 and insert into HPH to obtain plasmid pFC332-sgRNA-HPH; then cut with SWA1 and insert into 28Lacz to obtain plasmid pFC332-sgRNA-28Lacz-HPH. Cut plasmid pFC332-sgRNA-28Lacz-HPH with Age1 and insert into FUM1-N20 to obtain plasmid pFC332-sgRNA-28Lacz-HPH-sgFUM1; then cut the gene FUM1 upstream and downstream 1000-2000 bp as the same homologous arm. Cut plasmid pFC332-sgRNA-28Lacz-HPH-sgFUM1 with swa1 and insert into the upper homologous arm (the nucleotide sequence of the upper homologous arm is shown as SEQ ID NO. 26), then cut with Pme1 and insert into the lower homologous arm (the nucleotide sequence is shown as SEQ ID NO. 27), finally obtain the backbone plasmid pFC332-sgRNA-28Lacz-HPH-△FUM1. Cut the backbone plasmid and fragment plasmid (screening marker gene HPH, Pdes, kaurene oxidase gene, Tdes, Pcox7c, kaurenoic acid 13-hydroxylase gene and Ttef) with Bsmb1 respectively, then according to the system add the vector and equimolar fragments, and after the connection of the fragments and the backbone, it is found that the recombinant vector steviol glycoside has the highest yield as shown in Table 1, i.e. the combination of promoters Pdes and Pcox7c achieves the highest yield of steviol glycoside. Figure 3 As shown in Table 1, the corresponding six promoters can be divided into three types of high, medium and low intensity according to the ability to drive gene transcription, i.e. high intensity: PDES and PCOX7C, medium intensity: PGPD and PTRPC, and low intensity: PGLNA and PGPDA. Using three different endogenous promoters with high, medium and low transcription activity to control the transcription intensity of two genes encoding steviol glycoside pathway, fine-tune gene expression and improve pathway efficiency.
[0051] S3, transformation experiment, take 100 μL of G. fujikuroi protoplasts, add 50 μL of STC solution (a kind of osmotic pressure stable transformation buffer), add 10 μg of recombinant vector obtained in step S2, mix and then ice bath for 20 minutes, then add 50 μL of 25% by weight PEG6000 solution (1M sorbitol, 10 mM Tris-Cl, 50 mM CaCl2, pH = 7.5), mix and then ice bath for 20 minutes; add 1 mL of PEG6000 solution, mix at room temperature for 5 min, then add 2 mL of STC solution, mix and then coat on MYG solid regeneration plate (20 g / L glucose; 3 g / L peptone; 3 g / L yeast extract; 171.25 g / L sucrose; 20 g / L agar powder; all purchased from Macklin), culture for 12 h, then overlay 10 mL of 100 μg / ml concentration of hygromycin soft agar regeneration plate, and wait for the appearance of transformants.
[0052] S4, genome verification: extract the genome of G. fujikuroi by fungal genome DNA extraction kit (purchased from Beijing Solabio Technology Co., Ltd.); perform genome fragment amplification reaction in a 20 μL amplification system, the amplification system: 10 μL 2x Phanta Flash Master Mix (from Nanjing Vazyme); verification primers: FUM1-JY-F: GCGGAAAGAACATAGAGAGC; FUM1-JY-R: GTGATCATGACTGCGGTGATC.
[0053] Genome verification: extract the genome of G. fujikuroi by fungal genome DNA extraction kit (purchased from Beijing Solabio Technology Co., Ltd.). Perform genome fragment amplification reaction in a 20 μL amplification system, the amplification system contains 10 μL 2x Phanta Flash Master Mix (from Nanjing Vazyme). The verification primers are FUM1-JY-F: GCGGAAAGAACATAGAGAGC and FUM1-JY-R: GTGATCATGACTGCGGTGATC. The amplification reaction conditions are set as follows: 95°C pre-denaturation for 3 minutes; then 35 cycles of 95°C denaturation for 15 seconds, 55°C annealing for 15 seconds, and 72°C extension for 30 seconds; finally 72°C terminal extension for 5 minutes. The amplification product is detected by 1% agarose gel electrophoresis. The results show specific bands of the expected size, which can determine that the target gene GUS has been successfully inserted into the genome of G. fujikuroi, and stable transformants are obtained.
[0054] Example 3 The transformants obtained in the above experiment were subjected to fermentation experiment, including the following steps: S1, fermentation experiment: the original Gibberella and the recombinant Gibberella strain (recombinant strain I) constructed by Golden Gate system and containing specific promoter combination (PDES+PCOX7C) and steviol glycoside synthesis pathway in example 2 were inoculated into seed culture medium (the composition of seed culture medium was 3.5% by weight of glucose, 2% by weight of soybean powder, 1.1% by weight of peanut powder, 3% by weight of dextrin, 0.12% by weight of KH2PO4, 0.02% by weight of (NH4)2SO4, 0.1% by weight of anhydrous magnesium sulfate), 30℃, 200 rpm for 16 h, and then transferred to fermentation culture medium (the composition of fermentation culture medium was 5% by weight of starch, 1.5% by weight of peanut powder, 1% by weight of soybean powder, 0.12% by weight of soybean oil, 0.15% by weight of magnesium sulfate heptahydrate, 0.025% by weight of (NH4)2SO4, 0.2% by weight of KH2PO4, 0.005% by weight of ZnSO4, 0.0075% by weight of MnSO4) at a volume ratio of 10% inoculation amount, 30℃, 200 rpm for 5 days of fermentation, then the culture was filtered to obtain fermentation supernatant, and then high performance liquid chromatography was used to detect the yield of steviol glycoside.
[0055] S2, high performance liquid detection method: the mobile phase was acetonitrile / water (80:20), the pretreated sample was separated at a flow rate of 1.0 mL / min, the detection wavelength was 210 nm, and the injection amount was 4 μL.
[0056] The results are shown in Figure 4 The results are shown in
[0057] This example shows that the Golden Gate system constructed by the application can effectively drive the expression of key genes in the steviol glycoside synthesis pathway, proving the feasibility of the Golden Gate system provided by the application in the application of steviol glycoside biosynthesis.
[0058] Example 4 The method of example 3 was used, except that the recombinant strain I was replaced by recombinant strain II (containing specific promoter combination PGDP+Pdes), which was set as G2 group, and the yield of steviol glycoside obtained is shown in table 1.
[0059] Example 5 The method of example 3 was used, except that the recombinant strain I was replaced by recombinant strain III (containing specific promoter combination PGLNA+PGPDA), which was set as G3 group, and the yield of steviol glycoside obtained is shown in table 1.
[0060] Example 6 The method of Example 3 was followed, except that the fermentation medium composition was adjusted to starch 4.5 wt%, peanut powder 1 wt%, soybean powder 0.8 wt%, soybean oil 0.1 wt%, magnesium sulfate heptahydrate 0.1 wt%, (NH4)2SO40.02 wt%, KH2PO40.15 wt%, ZnSO40.004 wt%, MnSO40.007 wt%, and set as G4 group, and the resulting steviol glycoside yield is shown in Table 1.
[0061] Example 7 The method of Example 3 was followed, except that the fermentation medium composition was adjusted to starch 5.5 wt%, peanut powder 2 wt%, soybean powder 1.2 wt%, soybean oil 0.14 wt%, magnesium sulfate heptahydrate 0.2 wt%, (NH4)2SO40.03 wt%, KH2PO40.25 wt%, ZnSO40.006 wt%, MnSO40.008 wt%, and set as G5 group, and the resulting steviol glycoside yield is shown in Table 1.
[0062] Comparative Example 1 The method of Example 3 was followed, except that the recombinant strain I was replaced by recombinant strain IV (containing only one promoter I PGDP and not containing terminator I), and set as G4 group, and the resulting steviol glycoside yield is shown in Table 1.
[0063] Example 8 The method of Example 3 was followed, except that the fermentation medium composition was adjusted to starch 3 wt%, peanut powder 5 wt%, soybean powder 0.5 wt%, soybean oil 0.2 wt%, magnesium sulfate heptahydrate 0.5 wt%, (NH4)2SO40.05 wt%, KH2PO40.05 wt%, ZnSO40.01 wt%, MnSO40.01 wt%, and set as G6 group, and the resulting steviol glycoside yield is shown in Table 1.
[0064] Example 9 The method of Example 3 was followed, except that the starch in the fermentation medium was adjusted to 4.5 wt% glucose, the peanut powder and soybean powder were adjusted to 0.8 wt% defatted soybean meal, the content of magnesium sulfate heptahydrate was adjusted to 0.1 wt%, and the content of potassium bisulfate was adjusted to 0.15 wt%, and set as G7 group, and the resulting steviol glycoside yield is shown in Table 1. Table 1
[0065] As can be seen from the results in Table 1, the use of Example 3 of the present application has a significantly better effect on the synthesis of steviol glycosides.
[0066] The preferred embodiments of the present application are described in detail above, but the present application is not limited thereto. Various simple modifications can be made to the technical solutions of the present application within the technical concept of the present application, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be considered as disclosed by the present application and fall within the protection scope of the present application.
Claims
1. A Golden-Gate assembly system, characterized in that, The assembly system contains, in sequence, a linker sequence I, a selectable marker gene, a linker sequence II, a promoter I, a linker sequence III, a kaurene oxidase gene, a linker sequence IV, a terminator I, a linker sequence V, a promoter II, a linker sequence VI, a kaurene 13-hydroxylase gene, a linker sequence VII, a terminator II, and a linker sequence VIII.
2. The Golden-Gate assembly system according to claim 1, characterized in that, The nucleotide sequences of the linker sequence I are shown in SEQ ID NO. 1, the linker sequence II are shown in SEQ ID NO. 2, the linker sequence III are shown in SEQ ID NO. 3, the linker sequence IV are shown in SEQ ID NO. 4, the linker sequence V are shown in SEQ ID NO. 5, the linker sequence VI are shown in SEQ ID NO. 6, the linker sequence VII are shown in SEQ ID NO. 7, and the linker sequence VIII are shown in SEQ ID NO.
8. The promoter I and promoter II are each independently selected from any one of PGPD, PTRPC, PPGDA, PGLNA, PCOX7C and PDES; Preferably, promoter I is PGPD and its nucleotide sequence is as shown in SEQ ID NO. 9; Preferably, the promoter II is PTRPC and its nucleotide sequence is shown in SEQ ID NO.
10.
3. The Golden-Gate assembly system according to claim 1 or 2, characterized in that, The selection marker gene is selected from any one of the following: hygromycin resistance gene HPH, ampicillin resistance gene AmpR, kanamycin resistance gene KanR, and bleomycin resistance gene BleR.
4. The Golden-Gate assembly system according to claim 1 or 2, characterized in that, The terminator I and terminator II are each independently selected from any one of TTRPT, TTRPC, TTDES, TPYK1, GGPPt and TTEF.
5. The Golden-Gate assembly system according to claim 1 or 2, characterized in that, The nucleotide sequence of the kauriene oxidase gene is shown in SEQ ID NO.
11.
6. The Golden-Gate assembly system according to claim 1 or 2, characterized in that, The nucleotide sequence of the kaurene 13-hydroxylase is shown in SEQ ID NO.
12.
7. A recombinant bacterial strain, characterized in that, The recombinant strain contains the Golden-Gate assembly system according to any one of claims 1-6.
8. A method for constructing a recombinant bacterial strain, characterized in that, The method includes: introducing the Golden-Gate assembly system according to any one of claims 1-6 into the starting strain; Preferably, the starting strain is *Fujikura fusiforme*.
9. The use of the Golden-Gate assembly system according to any one of claims 1-6, the recombinant strain according to claim 7, and the recombinant strain constructed by the method according to claim 8 in the production of steviol glycosides.
10. A method for producing steviol glycosides, characterized in that, The method involves inoculating the recombinant strain of claim 7 and / or the recombinant strain constructed by the method of claim 8 into a fermentation medium for fermentation culture. Preferably, the fermentation medium contains 4.5-5.5% by weight starch, 1-2% by weight peanut powder, 0.8-1.2% by weight soybean powder, 0.1-0.14% by weight soybean oil, 0.1-0.2% by weight magnesium sulfate heptahydrate, 0.02-0.03% by weight ammonium sulfate, 0.15-0.25% by weight potassium bisulfate, 0.004-0.006% by weight zinc sulfate and 0.007-0.008% by weight magnesium sulfate; Preferably, the fermentation conditions include: a temperature of 25-35℃, a rotation speed of 150-250 rpm, and a time of 4-6 days.
